Banava Sepideh, Houshyari Mohammad, Safaie Tahmineh
DDS, M.Sc. in Restorative Dentistry and Dental Materials, Assistant Professor, Islamic Azad University, Dental Branch, Tehran, Iran.
Assistant Professor, Shohada-e-Tajrish Hospital, Department of Radiation Oncology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Electron Physician. 2015 Nov 20;7(7):1535-41. doi: 10.19082/1535. eCollection 2015 Nov.
Oral and saliva conditions of patients undergoing chemotherapy is often affected by the medication they receive. Up to now, no appropriate medication that possesses the positive effects of chemotherapy without presenting oral complications has been introduced.
The aim of this study was to assess the clinical effects of CPP-ACPF paste on the oral and salivary status of patients undergoing chemotherapy.
From October 2013 to April 2014, 20 patients in chemotherapy treatment plans and who met the inclusion criteria enrolled in this randomized parallel single-blind controlled clinical trial in Shohada-e-Tajrish Hospital in Tehran, Iran. Patients were divided into two groups: 1) patients received their daily medication of cancer therapy center (group 1, control); 2) patients applied CPP-ACPF Crème (MI paste plus, GC USA) twice a day as instructed (group 2). The baseline status of oral conditions of patients (mucositis, dry mouth, infection, diminished tasting sense, difficulty in food intake, burning sensation of mucosa, saliva and dental plaque pH, rest and stimulated saliva, buffering capacity of saliva) were recorded and reevaluated after 21 and 42 days. The data were analyzed with a Mann-Whitney U-test.
A total of 20 patients were allocated randomly to groups 1 and 2. The Mann-Whitney U-test showed that application of CPP-ACPF paste twice daily did not cause any significant difference in oral complication of the subject group compared with the control group (p>0.05). Among salivary signs, resting and stimulated saliva rates and saliva buffering capacity had significantly altered in the CPP-ACPF group in day 21 and 42 in comparison with those of the control group (p<0.05).
Application of CPP-ACPF paste before and during chemotherapy can improve the salivary status of patients undergoing this treatment.
接受化疗患者的口腔和唾液状况常受所服药物影响。截至目前，尚未推出一种既具有化疗积极效果又无口腔并发症的合适药物。
本研究旨在评估酪蛋白磷酸肽-无定形磷酸钙氟化物（CPP-ACPF）糊剂对接受化疗患者口腔和唾液状况的临床效果。
2013年10月至2014年4月，20例符合纳入标准且正在接受化疗方案的患者参与了伊朗德黑兰塔吉里什烈士医院的这项随机平行单盲对照临床试验。患者分为两组：1）接受癌症治疗中心日常药物治疗的患者（第1组，对照组）；2）患者按指示每天两次使用CPP-ACPF乳膏（MI糊剂加，美国GC公司）（第2组）。记录患者口腔状况的基线状态（口腔黏膜炎、口干、感染、味觉减退、进食困难、黏膜烧灼感、唾液和牙菌斑pH值、静息和刺激唾液、唾液缓冲能力），并在21天和42天后重新评估。数据采用曼-惠特尼U检验进行分析。
共20例患者随机分配至第1组和第2组。曼-惠特尼U检验显示，与对照组相比，每日两次应用CPP-ACPF糊剂在受试组口腔并发症方面未引起任何显著差异（p>0.05）。在唾液指标中，与对照组相比，CPP-ACPF组在第21天和42天的静息和刺激唾液率以及唾液缓冲能力有显著变化（p<0.05）。
化疗前及化疗期间应用CPP-ACPF糊剂可改善接受该治疗患者的唾液状况。
